CAR T cells are a highly active field of investigation, with many companies at work on formulations they hope to bring to market, but these agents have limitations, particularly with metastasized solid tumors. Read More >>
Blinatumomab (Blincyto) received an 8 to 4 vote from the FDA’s Oncologic Drugs Advisory Committee in favor of an indication for the treatment of MRD-positive B-cell precursor acute lymphoblastic leukemia.
Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now